Centro Médico Teknon
Immunotherapy for lung cancer in Spain costs from $30,000 to $60,000 on average. Final pricing depends on the specific drug used, the number of infusion cycles, and the hospital location. Patients save around 50% compared to the US, where this treatment costs $90,000 on average. Most private medical centers include oncologist consultations, nursing care, and routine laboratory monitoring in their service fees.
Bookimed Expert Insight: Choosing JCI-accredited centers in Barcelona provides access to world-class oncology leaders like Dr. Enriqueta Felip. These top-tier facilities, such as Centro Médico Teknon, combine high volume—handling 23,500 operations annually—with elite credentials. While basic immunotherapy starts at lower price points, the real value in Spain lies in integrated care. Large networks like HM Hospitals offer specialized radiotherapy units that complement immunotherapy for better outcomes.
Why choose Spain for immunotherapy for lung cancer?
Access advanced Immunotherapy for lung cancer solutions in trusted clinics .
| Turkey | Austria | Spain | |
| Immunotherapy for lung cancer | from $18,000 | from $30,000 | from $30,000 |
Day 1 - Arrival
Day 2 - Pre-operation
Day 3 - Immunotherapy
Day 4 - Post-operation
Week 1 - Rehabilitation
Week 2 - Rehabilitation
Please keep in mind that each patient"s journey is unique and can vary. Always follow the specific advice provided by your medical team.
Dr. Vergés is a distinguished ophthalmologist with a PhD from Harvard and multiple national research awards, focusing on advanced eye care.
Leading expert in immunotherapy for lung cancer – Dr. Felip integrates novel immunotherapies into treatment protocols at Hospital Quiron Barcelona.
Dr. Joan Albanell Mestres is a leading oncologist who specializes in breast cancer. He earned his MBBS from the University Autónoma de Barcelona in 1989. He leads the breast cancer program at HM Delfos and oversees Oncology services at Clin del Mar in Spain.
Dr. Albanell has published 120 scientific articles, with over 9,000 citations. He directs cancer research at Del Mar. He is also an active member of GEICAM, CIBERONC, AIECA, and SEOM. He regularly contributes to important oncology research.